Ron Wyden @RonWyden
It's unconscionable to ask seniors and taxpayers to pay $56,000 a year for a drug that has yet to be proven effective. Medicare must be able to negotiate a fair price for prescription drugs. — PolitiTweet.org
Larry Levitt @larry_levitt
Biogen is pricing Aduhelm, its new Alzheimer's drug, at $56,000 per year. And, it's not even clear it works. https://t.co/evmHkK5zbI